Last reviewed · How we verify
Respigon (BUFOGENIN)
Respigon (generic name: BUFOGENIN) is a drug. It is currently in Phase 2 development.
Respigon works by interacting with a specific cellular target to produce a therapeutic effect.
Respigon (BUFOGENIN) is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. The drug's pharmacokinetic properties, including half-life and bioavailability, are also unknown. Further research is needed to understand its mechanism of action and potential therapeutic applications. As a result, key safety considerations and generic manufacturers are also unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BUFOGENIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your cells have locks on them, and Respigon has a key that fits into those locks. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as reducing inflammation or blocking a disease-causing process. This is a simplified explanation of how small molecules like Respigon can affect cellular behavior.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Respigon CI brief — competitive landscape report
- Respigon updates RSS · CI watch RSS
Frequently asked questions about Respigon
What is Respigon?
How does Respigon work?
What is the generic name of Respigon?
What development phase is Respigon in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing